Psychological Impact of Myasthenia Gravis: A Growing Area of Concern

People living with myasthenia gravis (MG) experience significantly higher rates of psychological distress, including depression and anxiety, sleep problems, and cognitive difficulties, compared to healthy individuals, according to recent research. The severity of the disease and the dosage of corticosteroids used for treatment are independently linked to increased psychiatric symptoms.

Understanding Myasthenia Gravis and its Psychological Toll

Myasthenia gravis is a rare autoimmune disorder where the immune system mistakenly attacks proteins crucial for nerve-muscle communication, most commonly acetylcholine receptors (AChRs). [1] This leads to muscle weakness and fatigue, particularly affecting voluntary movements. While MG is primarily recognized as a neuroimmunological condition, its impact extends beyond the physical realm.

Researchers emphasize that the psychological impact of MG is often overlooked, yet it’s a crucial aspect of patient care. Mood disorders, such as depression and anxiety, are reported in up to 41% of MG patients and can be misdiagnosed or undertreated. [3] heightened anxiety and depression can worsen MG symptoms and overall disease progression.

Italian Study Highlights Psychiatric Burden

A recent multicenter Italian study, published in the Journal of Neuroimmunology, retrospectively analyzed data from 116 MG patients followed at three Italian centers between 2020 and 2024. [3] A control group of 119 age- and sex-matched healthy individuals was included for comparison.

The study revealed that MG patients had significantly higher psychological distress, as measured by the Symptom Checklist-90 (SCL-90). Specifically, the MG group exhibited greater depression, anxiety, obsessive-compulsive traits, and somatization – expressing psychological distress through physical symptoms. They likewise reported more sleep disturbances and impairments in physical function and executive function (cognitive processes involved in planning, problem-solving, and decision-making).

Treatment Considerations and Psychological Impact

While there were no significant differences in neuropsychiatric burden between MG patients taking or not taking corticosteroids, a higher dose of prednisone (above 15 mg/day) was significantly associated with psychiatric problems like anxiety and depression. [3] The immunosuppressant azathioprine was linked to sleep disturbances and somatization, while higher doses of Mestinon (pyridostigmine) were associated with paranoia.

Interestingly, men generally reported higher psychological distress and depressive symptoms than women, while those with early-onset MG experienced greater psychological distress but less cognitive impairment. Specific MG symptoms also correlated with psychological issues; for example, swallowing difficulties were linked to higher levels of somatization and anxiety, and double vision was associated with sleep disturbances.

The Importance of a Multidisciplinary Approach

The study underscores the need for a multidisciplinary approach to MG management that incorporates psychiatric evaluation, cognitive assessment, and personalized interventions to improve quality of life. [3] Integrated neuropsychiatric monitoring is crucial for MG patients, particularly given the significant psychiatric burden associated with the disease and the potential side effects of treatments like corticosteroids.

Corticosteroids, while often used for short-term symptom relief due to their rapid response and low cost, [3] carry a risk of psychiatric side effects, especially at higher doses. [4] Strategies to minimize steroid intake, such as the apply of non-steroidal immunosuppressants, are important to reduce these risks. [2]